Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer (Q45357596)

13 December 2017

title

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer (English)

1 reference

13 December 2017

main subject

phase I clinical trial

0 references

1 reference

1 reference

4

1 reference

13 December 2017

14

1 reference

13 December 2017

8

Keith T Flaherty

1 reference

13 December 2017

9

Bruce J Giantonio

1 reference

13 December 2017

Christine A Ciunci

1

1 reference

13 December 2017

Rodolfo F Perini

2

1 reference

13 December 2017

Anjali N Avadhani

3

1 reference

13 December 2017

Weijing Sun

5

1 reference

13 December 2017

Maryann Redlinger

6

1 reference

13 December 2017

Kathleen Harlacker

7

1 reference

13 December 2017

Mark A Rosen

10

1 reference

13 December 2017

Chaitanya R Divgi

11

1 reference

13 December 2017

Hee Kwon Song

12

1 reference

13 December 2017

Sarah Englander

13

1 reference

13 December 2017

Mitchell Schnall

15

1 reference

13 December 2017

Peter J O'Dwyer

16

1 reference

13 December 2017

language of work or name

English

0 references

publication date

24 September 2013

1 reference

13 December 2017

1 reference

13 December 2017

volume

120

1 reference

13 December 2017

issue

1

1 reference

13 December 2017

page(s)

77-85

1 reference

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

PI3K/PTEN signaling in tumorigenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Respiratory motion-compensated radial dynamic contrast-enhanced (DCE)-MRI of chest and abdominal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

k-space weighted image contrast (KWIC) for contrast manipulation in projection reconstruction MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28294

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28294

1 reference

13 December 2017

1 reference